Every year, the best funds and investment companies that show a constantly high, risk-adjusted performance within their comparison group are awarded with the Lipper Fund Awards. This year, our biotechnology equity fund got full marks in Germany over a time period of five years, compared to all other international biotechnology funds.
In the Erste Asset Management TV, fund manager Harald Kober talks about the causes of this positive development, investment strategies and future prospects.
[iframe src=”http://www.youtube.com/embed/Js4Qo_AJkrM” width=”100%” height=”500″]